)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gentian Diagnostics
Gentian Diagnostics (GENT) investor relations material
Gentian Diagnostics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary20 Oct, 2026
Executive summary
Record Q3 sales of NOK 51.1m, up 22% reported and 30% currency-neutral organically; EBITDA was NOK 13.6m.
Seven assay development projects and one technology project were active; Europe and the US led quarterly growth.
Financial highlights
Q3 revenue was NOK 51.1m versus NOK 41.8m; 9M revenue was NOK 144.8m versus NOK 129.9m, up 11% reported and 17% currency-neutral organically.
Q3 operating profit was NOK 11.4m and net profit NOK 7.3m; 9M operating loss was NOK 10.2m and net loss NOK 8.5m, including a NOK 30.2m non-cash impairment.
Q3 operating cash flow was NOK 14.9m; 9M operating cash flow was negative NOK 0.9m, mainly reflecting a NOK 17.8m increase in receivables.
Q3 operating expenses were NOK 21.8m; underlying 9M OPEX rose 4.5%, reflecting higher activity and general cost increases.
Outlook and guidance
Strong Q4 order intake supports expected full-year 2026 Cystatin C growth; the key IVD partner assay remains on track for Q4 2027 launch.
Long-term targets are a 55%-60% gross margin and 40% EBITDA margin; new projects target return on capital employed above 20%.
Pipeline commercialization horizons span 12-36+ months; timing depends on technical progress, partners and regulatory requirements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gentian Diagnostics
- Record Q2 sales, margin gains, and new R&D strategy drive growth despite China headwinds.GENT
Q2 2026 - Q1 2026 saw stable sales, lower margins, and a NOK 30.2 million R&D impairment.GENTQ1 2026
- Record sales, 32% Cystatin C growth, margin gains, and new global partnership in 2025.GENTQ4 2025
- Q3 2025 saw 28% sales growth, 56% margin, and strong US momentum despite China risks.GENTQ3 2025
- Q2 2025 sales up 14% YoY, but gross margin dropped to 44% and net loss was NOK 2 million.GENTQ2 2025
- EBITDA and gross margin rose on strong fCALⓇ turbo sales; NT-proBNP advanced, China lagged.GENTQ3 2024
- Q2 2024 delivered 12% sales growth, margin gains, and pipeline milestones amid China headwinds.GENTQ2 2024
- Record Q1 2025 sales, margin expansion, and global growth in core diagnostic products.GENTQ1 2025
- Record sales, margin gains, and a NOK 0.40 dividend proposal highlight strong 2024 results.GENTQ4 2024
Next Gentian Diagnostics earnings date
Q4 202610 Feb, 2027
Gentian Diagnostics
Next Gentian Diagnostics earnings date
Q4 202610 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Gentian Diagnostics ASA is a Norwegian company that specializes in the development and production of in-vitro diagnostic (IVD) reagents. The company’s focus is on creating biochemical reagents for use in clinical chemistry analyzers, particularly utilizing Particle-Enhanced Turbidimetric Immunoassays (PETIA). These assays enable faster, automated testing for various medical conditions, improving operational efficiency for clinical labs. Gentian’s products target key areas such as infections, inflammation, kidney disease, cardiac conditions, and veterinary medicine. Gentian Diagnostics is headquartered in Moss, Norway, and its shares are listed on the Oslo Stock Exchange.